Pluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine

Genetics Investing

Pluristem Therapeutics (Nasdaq:PSTI)  a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study of PLX-R18 that demonstrate the cells’ efficacy in improving human hematopoietic engraftment. The article titled, “Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model” was …

Pluristem Therapeutics (Nasdaq:PSTI)  a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study of PLX-R18 that demonstrate the cells’ efficacy in improving human hematopoietic engraftment. The article titled, “Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model” was published in the peer-reviewed journal’s February 2018 issue.

As quoted in the press release:

In the published study, mice were injected intramuscularly (IM) with PLX-R18 following human hematopoietic cell transplantation (HCT). Significant improvement was observed in the peripheral blood counts as measured by CD45+ cell recovery at weeks 6 (8.4 vs. 24.1%, p < 0.001) and 8 (7.3 vs. 13.1%, p < 0.05) and in the bone marrow at week 8 (28 vs. 40.0%, p < 0.01) in the PLX-R18 treated groups versus the control, placebo groups. Superiority of PLX-R18 treatment over the control groups was also reported for recovery of CD19+ cells at weeks 6 (12.6 vs. 3.8%) and 8 (10.1 vs. 4.1%). These findings support Pluristem’s clinical development of PLX-R18 for a variety of hematological indications.

Click here to read the full press release.

The Conversation (0)
×